SOCIEDADE BENEF ISRAELITABRAS HOSPITAL ALBERT EINSTEIN

🇧🇷Brazil

Country: 🇧🇷Brazil

Ownership: Private

Established: 1971-01-01

Employees: 10K

Market Cap: -

Website: https://www.einstein.br

Clinical Trials

Impact of Yoga and Gentle Massage Practices on Symptom Management in Patients Undergoing HSCT

Not Applicable

Completed

Conditions: Hematopoietic Stem Cell Transplantation
Bone Marrow Transplantation

Interventions: Behavioral: yoga or gentle massage plus standard treatment for HSCT

First Posted Date: 2023-11-07

Last Posted Date: 2025-03-20

Lead Sponsor: Hospital Israelita Albert Einstein

Target Recruit Count: 35

Registration Number: NCT06118853

Locations: 🇧🇷
Maria Ester Azevedo Massola, São Paulo, SP, Brazil

Expansion of Virus-Specific Lymphocytes for Cell Therapy

Phase 1

Recruiting

Conditions: CMV
CMV Viremia

Interventions: Combination Product: Lymphocyte infusion (ImmuneCellVir-I)

First Posted Date: 2023-08-25

Last Posted Date: 2024-10-24

Lead Sponsor: Hospital Israelita Albert Einstein

Target Recruit Count: 10

Registration Number: NCT06011486

Locations: 🇧🇷
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil

Evaluation of the Clinical Impact of Different Telemedicine Practices in Intensive Care Units

Not Applicable

Not yet recruiting

Conditions: Telemedicine
Critical Care
Intensive Care Units

Interventions: Other: Intervention period

First Posted Date: 2023-07-27

Last Posted Date: 2023-10-17

Lead Sponsor: Hospital Israelita Albert Einstein

Target Recruit Count: 25000

Registration Number: NCT05960994

Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension

Phase 3

Recruiting

Conditions: Hypertension

Interventions: Drug: candesartan cilexetil + chlorthalidone + amlodipine
Drug: Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg)

First Posted Date: 2023-06-27

Last Posted Date: 2023-08-24

Lead Sponsor: Hospital Israelita Albert Einstein

Target Recruit Count: 698

Registration Number: NCT05920005

Locations: 🇧🇷
Vitoria Clinical Research Institute LTDA, Vitória, Espírito Santo, Brazil
🇧🇷
Instituto Atena de Pesquisa Clinica LTDA, Natal, Rio Grande Do Norte, Brazil
🇧🇷
Centro de Pesquisas Clinicas Dr. Marco Mota (Centro Universitario Cesmac/ Hospital do Coração de Alagoas), Maceió, Alagoas, Brazil

and more 19 locations

Patients Undergoing Continuous Venovenous Hemodiafiltration: Effects of Increased Blood Flow

Not Applicable

Active, not recruiting

Conditions: Acute Kidney Injury

Interventions: Other: Effects of increased blood flow during regional anticoagulation with 4% trisodium citrate in patients undergoing continuous venovenous hemodiafiltration

First Posted Date: 2023-04-03

Last Posted Date: 2024-06-10

Lead Sponsor: Hospital Israelita Albert Einstein

Target Recruit Count: 27

Registration Number: NCT05796661

Locations: 🇧🇷
Hospital Israelite Albert Einstein, São Paulo, Brazil

Observational, Prospective, Cohort Study of Mpox Infection in Brazil (NETPOX)

Recruiting

Conditions: Monkeypox
MPOX

Interventions: Diagnostic Test: Viral genomic
Diagnostic Test: Untargeted Metabolomics

First Posted Date: 2023-03-24

Last Posted Date: 2024-07-17

Lead Sponsor: Hospital Israelita Albert Einstein

Target Recruit Count: 80

Registration Number: NCT05784038

Locations: 🇧🇷
Hospital Naval Marcílio Dias, Rio De Janeiro, Brazil
🇧🇷
Hospital Universitário João de Barros Barreto, Belem, Para, Brazil
🇧🇷
Hospital Israelita Albert Einstein, São Paulo, Sao Paulo, Brazil

Platelet Sub-study of the Neomindset Trial

Phase 4

Active, not recruiting

Conditions: Acute Coronary Syndrome

First Posted Date: 2023-03-14

Last Posted Date: 2025-04-08

Lead Sponsor: Hospital Israelita Albert Einstein

Target Recruit Count: 48

Registration Number: NCT05767723

Locations: 🇧🇷
Hospital Israelita Albert Einstein, São Paulo, Brazil

A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies

Phase 1

Not yet recruiting

Conditions: Acute Lymphoblastic Leukemia Refractory
B-cell Lymphoma Refractory
B-cell Lymphoma Recurrent
Acute Lymphoblastic Leukemia, in Relapse
Chronic Lymphocytic Leukemia Recurrent
Chronic Lymphocytic Leukemia Refractory

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0

First Posted Date: 2023-01-31

Last Posted Date: 2023-01-31

Lead Sponsor: Hospital Israelita Albert Einstein

Target Recruit Count: 30

Registration Number: NCT05705570

Locations: 🇧🇷
Hospital Israelita Albert Einstein, São Paulo, Brazil

Use of Low-level Laser Therapy in the Treatment of Incontinence-associated Dermatitis in the Elderly

Not Applicable

Completed

Conditions: Dermatitis

Interventions: Other: Gentle intimate hygiene and skin protective barrier application - Erythema with signs of epidermis loss
Other: Gentle intimate hygiene and skin protective barrier application - Persistent erythema with intact epidermis
Other: Low Level Laser Therapy - Persistent erythema with intact epidermis
Other: Low Level Laser Therapy - Erythema with signs of epidermis loss

First Posted Date: 2023-01-26

Last Posted Date: 2023-09-13

Lead Sponsor: Hospital Israelita Albert Einstein

Target Recruit Count: 16

Registration Number: NCT05699122

Locations: 🇧🇷
Hospital Israelita Albert Einstein, São Paulo, Brazil

Impact of Telehealth Education in Diabetes Patients

Not Applicable

Not yet recruiting

Conditions: Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Behavioral: Ampiled Education
Behavioral: Standard education

First Posted Date: 2023-01-25

Last Posted Date: 2023-01-30

Lead Sponsor: Hospital Israelita Albert Einstein

Target Recruit Count: 200

Registration Number: NCT05696015

Home Terms & Conditions Privacy Policy